Glaukos (GKOS) – Investment Analysts’ Weekly Ratings Changes

Glaukos (NYSE: GKOS) recently received a number of ratings updates from brokerages and research firms:

• 7/30/2026 – Glaukos had its price target raised by HC Wainwright from $168.00 to $195.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Glaukos had its price target raised by Stifel Nicolaus from $175.00 to $190.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Glaukos had its price target raised by Citigroup Inc. from $175.00 to $188.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Glaukos had its “overweight” rating reaffirmed by Piper Sandler. They now have a $195.00 price target on the stock, up from $165.00.
• 7/30/2026 – Glaukos had its price target raised by Wells Fargo & Company from $138.00 to $178.00. They now have an “overweight” rating on the stock.
• 7/30/2026 – Glaukos had its price target raised by Needham & Company LLC from $150.00 to $201.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Glaukos had its price target raised by Truist Financial Corporation from $180.00 to $215.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Glaukos had its price target raised by BTIG Research from $164.00 to $193.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Glaukos is now covered by UBS Group AG. They set a “neutral” rating and a $150.00 price target on the stock.
• 7/28/2026 – Glaukos is now covered by UBS Group AG. They set a “neutral” rating on the stock.
• 7/18/2026 – Glaukos was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/17/2026 – Glaukos had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/17/2026 – Glaukos had its price target raised by Stifel Nicolaus from $170.00 to $175.00. They now have a “buy” rating on the stock.
• 7/16/2026 – Glaukos had its price target raised by Truist Financial Corporation from $160.00 to $180.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Glaukos had its “buy” rating reaffirmed by BTIG Research. They now have a $164.00 price target on the stock.
• 7/8/2026 – Glaukos had its price target raised by Citigroup Inc. from $162.00 to $175.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Glaukos is now covered by HC Wainwright. They set a “buy” rating and a $168.00 price target on the stock.
• 7/6/2026 – Glaukos is now covered by HC Wainwright. They set a “buy” rating and a $168.00 price target on the stock.
• 7/4/2026 – Glaukos was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/1/2026 – Glaukos had its “overweight” rating reaffirmed by Piper Sandler. They now have a $165.00 price target on the stock.
• 6/21/2026 – Glaukos was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/17/2026 – Glaukos had its price target raised by Needham & Company LLC from $136.00 to $150.00. They now have a “buy” rating on the stock.
• 6/13/2026 – Glaukos was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/11/2026 – Glaukos had its price target raised by Citigroup Inc. from $140.00 to $162.00. They now have a “buy” rating on the stock.
• 6/10/2026 – Glaukos had its “buy” rating reaffirmed by BTIG Research. They now have a $162.00 price target on the stock.

Insider Transactions at Glaukos

In related news, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total transaction of $703,800.00. Following the completion of the sale, the director directly owned 35,528 shares in the company, valued at approximately $5,000,921.28. The trade was a 12.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Alex R. Thurman sold 10,000 shares of the stock in a transaction on Thursday, July 16th. The shares were sold at an average price of $160.00, for a total value of $1,600,000.00. Following the completion of the transaction, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at approximately $7,024,960. This represents a 18.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 61,273 shares of company stock valued at $9,082,003 over the last ninety days. Company insiders own 5.90% of the company’s stock.

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.